Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01161394 · ClinicalTrials.gov registry record · Phase 4
Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study
A Phase 4 study, sponsored by University at Buffalo.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT01161394: Completed Phase 4 study, sponsored by University at Buffalo.
NCT01161394 is a Phase 4 study that has completed, run by University at Buffalo. The registered enrollment target is 24 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01161394, a Phase 4 study, has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
Pioglitazone decreases oxidative load, inflammatory end points and improves vascular reactivity in obese patients in a dose dependent manner and that this effect is independent of its glucose lowering effects.
Primary Outcome
Percent change in NFkb at baseline and after 1, 2, 4, 6, and 12 weeks of pioglitazone therapy.
Interventions
- DRUG placebo
- DRUG Pioglitazone 15mg
- DRUG pioglitazone 30mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Est. Completion | 2003-10 |
| Phase | Phase 4 |
What the finished NCT01161394 record still lists
NCT01161394 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01161394 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01161394 about?
NCT01161394 is a clinical study titled "Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study". Pioglitazone decreases oxidative load, inflammatory end points and improves vascular reactivity in obese patients in a dose dependent manner and that this effect is independent of its glucose lowering effects.
What is the current status of trial NCT01161394?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. Estimated completion is 2003-10.
What interventions are being tested in trial NCT01161394?
The interventions under investigation include: placebo (DRUG), Pioglitazone 15mg (DRUG), pioglitazone 30mg (DRUG).
Who is sponsoring clinical trial NCT01161394?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01161394's enrollment target sits among peer trials
24 1699th of 2000 higher than 276 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant